Annual Financials for Sotera Health Co.
Fiscal year is January-December. All values USD millions. |
2018 | 2019 | 2020 | 2021 | 2022 |
5-year trend |
Sales/Revenue
|
746.15M | 778.33M | 818.16M | 931.48M | 1B | |
Sales Growth |
- | 4.31% | 5.12% | 13.85% | 7.75% | |
Cost of Goods Sold (COGS) incl. D&A |
446.87M | 441.46M | 433.62M | 476.59M | 509.62M | |
COGS excluding D&A |
298.73M | 292.69M | 288.11M | 323.43M | 361.88M | |
Depreciation & Amortization Expense |
148.15M | 148.77M | 145.51M | 153.15M | 147.75M | |
Depreciation |
68.24M | 68.72M | 65.26M | 66.41M | 66.19M | |
Amortization of Intangibles |
79.91M | 80.05M | 80.25M | 86.74M | 81.55M | |
COGS Growth |
- | -1.21% | -1.78% | 9.91% | 6.93% | |
Gross Income |
299.28M | 336.87M | 384.54M | 454.89M | 494.06M | |
Gross Income Growth |
- | 12.56% | 14.15% | 18.29% | 8.61% | |
Gross Profit Margin |
- | - | - | - | 49.22% | NA |
|
2018 | 2019 | 2020 | 2021 | 2022 |
5-year trend |
SG&A Expense |
118.65M | 130.68M | 126.97M | 154.48M | 164.57M | |
Research & Development |
- | - | - | - | - | |
Other SG&A |
118.65M | 130.68M | 126.97M | 154.48M | 164.57M | |
SGA Growth |
- | 10.13% | -2.83% | 21.67% | 6.53% | |
Other Operating Expense |
- | - | - | - | - | |
Unusual Expense |
100.87M | 51.9M | 92.99M | 61.98M | 500.09M | |
EBIT after Unusual Expense |
79.75M | 154.29M | 164.58M | 238.43M | (170.59M) | |
Non Operating Income/Expense |
87.72M | 2.18M | 6.52M | 12.66M | 19.85M | |
Non-Operating Interest Income |
- | - | - | - | - | |
Equity in Affiliates (Pretax) |
- | - | - | - | - | |
Interest Expense |
143.25M | 157.39M | 209.95M | 75.38M | 92.37M | |
Interest Expense Growth |
- | 9.87% | 33.39% | -64.10% | 22.54% | |
Gross Interest Expense |
143.25M | 157.39M | 210.65M | 76.48M | 96.07M | |
Interest Capitalized |
- | - | 700,000 | 1.1M | 3.7M | |
Pretax Income |
24.22M | (916,000) | (38.86M) | 175.72M | (243.11M) | |
Pretax Income Growth |
- | -103.78% | -4,142.36% | 552.18% | -238.35% | |
Pretax Margin |
- | - | - | - | -24.22% | NA |
Income Tax |
30.1M | 19.51M | (1.37M) | 58.6M | (9.54M) | |
Income Tax - Current Domestic |
27.18M | 21.62M | (10.39M) | 17.14M | 17.92M | |
Income Tax - Current Foreign |
48.23M | 16.89M | 32.39M | 45.18M | 46.5M | |
Income Tax - Deferred Domestic |
(17.83M) | (24.14M) | (9.67M) | (2.03M) | (70.3M) | |
Income Tax - Deferred Foreign |
(27.49M) | 5.14M | (13.69M) | (1.69M) | (3.66M) | |
Income Tax Credits |
- | - | - | - | - | |
Equity in Affiliates |
- | - | - | - | - | |
Other After Tax Income (Expense) |
- | - | - | (1.52M) | - | |
Consolidated Net Income |
(5.88M) | (20.43M) | (37.49M) | 115.6M | (233.57M) | |
Minority Interest Expense |
(6,000) | 425,000 | 1.13M | 239,000 | - | |
Net Income |
(5.87M) | (20.85M) | (38.62M) | 115.36M | (233.57M) | |
Net Income Growth |
- | -255.20% | -85.21% | 398.72% | -302.47% | |
Net Margin Growth |
- | - | - | - | -23.27% | NA |
Extraordinaries & Discontinued Operations |
- | - | - | - | - | |
Extra Items & Gain/Loss Sale Of Assets |
- | - | - | - | - | |
Cumulative Effect - Accounting Chg |
- | - | - | - | - | |
Discontinued Operations |
- | - | - | - | - | |
Net Income After Extraordinaries |
(5.87M) | (20.85M) | (38.62M) | 115.36M | (233.57M) | |
Preferred Dividends |
- | - | - | - | - | |
Net Income Available to Common |
(5.87M) | (20.85M) | (38.62M) | 115.36M | (233.57M) | |
EPS (Basic) |
(0.02) | (0.07) | (0.14) | 0.41 | (0.83) | |
EPS (Basic) Growth |
- | -255.83% | -85.95% | 403.08% | -301.86% | |
Basic Shares Outstanding |
284.42M | 284.42M | 283.25M | 279.23M | 280.1M | |
EPS (Diluted) |
(0.02) | (0.07) | (0.14) | 0.41 | (0.83) | |
EPS (Diluted) Growth |
- | -255.83% | -85.95% | 402.93% | -301.96% | |
Diluted Shares Outstanding |
284.42M | 284.42M | 283.25M | 279.38M | 280.1M | |
EBITDA |
328.77M | 354.96M | 403.08M | 453.56M | 477.25M | |
EBITDA Growth |
- | 7.97% | 13.56% | 12.52% | 5.22% | |
EBITDA Margin |
- | - | - | - | 47.55% | NA |